Danaher(US:DHR)2024-07-23 10:55Second Quarter 2024 Performance - Revenue decreased by 30% to $5743 million compared to $5912 million in Q2 2023[4, 5] - Core revenue declined by 35%[4] - Acquisitions contributed +20% to revenue[4] - Foreign exchange rates had a -15% impact on revenue[4] - Adjusted diluted net earnings per common share from continuing operations decreased by 06%[4] - Free cash flow performance decreased by 145%[6] - Adjusted operating profit margin increased by +60 BPS from 267% to 273%[6, 7] Segment Performance - Biotechnology revenue decreased by 90%, with core revenue down 70% and a 20% negative impact from FX[8] - Biotechnology adjusted operating profit margin increased by +20 BPS from 393% to 395%[8, 9] - Life Sciences revenue decreased by 15%, with core revenue down 55%, acquisitions contributing +60%, and a -20% impact from FX[10] - Life Sciences adjusted operating profit margin decreased by -360 BPS from 247% to 211%[10, 11] Forecasted Core Sales Decline and Adjusted Operating Profit Margin - The company forecasts a low-single digit percentage core sales decline for the three-month period ending September 27, 2024, compared to the comparable 2023 period[27] - The company forecasts a low-single digit percentage core sales decline for the year ending December 31, 2024, compared to the comparable 2023 period[27] - Adjusted operating profit margin is forecasted to be approximately 260% for the three-month period ending September 27, 2024[27] - Adjusted operating profit margin is forecasted to be approximately 290% for the year ending December 31, 2024[27]